



# Stabilis



## Cefazolin sodium



Noms commerciaux

|             |   |
|-------------|---|
| Acef        | Italie  |
| Ancef       | Etats Unis d'Amérique                                 |
| Basocef     | Allemagne   |
| Biofazolin  | Pologne   |
| Brizolina   | Espagne   |
| Cecan       | Pérou   |
| Cefabiozim  | Italie  |
| Cefacidal   | Chili, Colombie, Luxembourg, Maroc, Mexique, Pays bas |
| Cefadin     | Inde  |
| Cefamezin   | Tunisie   |
| Cefazil     | Italie  |
| Cefozin     | Turquie   |
| Cromezin    | Italie  |
| Eqizolin    | Turquie   |
| Fazoplex    | Espagne   |
| Intrazolina | Espagne   |
| Kefzol      | Autriche, Belgique, Suisse                            |
| Kurgan      | Espagne   |
| Nefazol     | Italie  |
| Recef       | Italie  |
| Sefamax     | Turquie   |
| Sefazol     | Turquie   |
| Sicef       | Italie  |
| Tasep       | Espagne   |
| Tecfazolina | Espagne   |
| Totacef     | Italie  |
| Vifazolin   | Grèce   |
| Zepilen     | Thaïlande   |
| Zolicef     | Autriche  |
| Zolival     | Espagne   |



### Stabilité des solutions

|  |  | 400 mg/ml | -20°C |  | 182 |  |  | 581 |
|--|--|-----------|-------|--|-----|--|--|-----|
|  |  | 10 mg/ml  | 25°C  |  | 48  |  |  | 418 |
|  |  | 400 mg/ml | -20°C |  | 182 |  |  | 581 |

|  |  |             |       |  |     |  |  |  |      |
|--|--|-------------|-------|--|-----|--|--|--|------|
|  |  | 10 mg/ml    | 2-8°C |  | 28  |  |  |  | 1452 |
|  |  | 10 mg/ml    | 25°C  |  | 7   |  |  |  | 1452 |
|  |  | 5 mg/ml     | -20°C |  | 182 |  |  |  | 581  |
|  |  | 73,2 mg/ml  | -20°C |  | 30  |  |  |  | 440  |
|  |  | 10 mg/ml    | -20°C |  | 48  |  |  |  | 582  |
|  |  | 20 mg/ml    | -20°C |  | 30  |  |  |  | 573  |
|  |  | 20 mg/ml    | 5°C   |  | 30  |  |  |  | 3230 |
|  |  | 40 mg/ml    | 5°C   |  | 30  |  |  |  | 3230 |
|  |  | 10 mg/ml    | 4°C   |  | 30  |  |  |  | 656  |
|  |  | 20 mg/ml    | -20°C |  | 30  |  |  |  | 576  |
|  |  | 0,5 mg/ml   | 25°C  |  | 8   |  |  |  | 2372 |
|  |  | 0,5 mg/ml   | 37°C  |  | 24  |  |  |  | 2372 |
|  |  | 0,5 mg/ml   | 4°C   |  | 14  |  |  |  | 2372 |
|  |  | 0,5 mg/ml   | 25°C  |  | 8   |  |  |  | 2372 |
|  |  | 0,5 mg/ml   | 37°C  |  | 24  |  |  |  | 2372 |
|  |  | 0,5 mg/ml   | 4°C   |  | 14  |  |  |  | 2372 |
|  |  | 0,333 mg/ml | 25°C  |  | 11  |  |  |  | 1979 |
|  |  | 0,333 mg/ml | 37°C  |  | 24  |  |  |  | 1979 |
|  |  | 0,333 mg/ml | 4°C   |  | 20  |  |  |  | 1979 |
|  |  | 0,333 mg/ml | 4°C   |  | 20  |  |  |  | 1979 |
|  |  | 0,5 mg/ml   | 25°C  |  | 7   |  |  |  | 1805 |
|  |  | 0,5 mg/ml   | 25°C  |  | 7   |  |  |  | 3888 |
|  |  | 0,5 mg/ml   | 37°C  |  | 24  |  |  |  | 1805 |
|  |  | 0,5 mg/ml   | 37°C  |  | 24  |  |  |  | 3888 |
|  |  | 0,5 mg/ml   | 4°C   |  | 30  |  |  |  | 1805 |
|  |  | 0,5 mg/ml   | 4°C   |  | 14  |  |  |  | 3888 |
|  |  | 10 mg/ml    | 2-8°C |  | 28  |  |  |  | 1452 |
|  |  | 10 mg/ml    | 25°C  |  | 7   |  |  |  | 1452 |
|  |  | 10 mg/ml    | 23°C  |  | 5   |  |  |  | 1840 |
|  |  | 10 mg/ml    | 4°C   |  | 30  |  |  |  | 1840 |
|  |  | 100 mg/ml   | 5°C   |  | 30  |  |  |  | 3230 |
|  |  | 200 mg/ml   | 5°C   |  | 30  |  |  |  | 3230 |
|  |  | 333 mg/ml   | -20°C |  | 270 |  |  |  | 574  |

|  |  |              |         |  |    |  |  |  |      |
|--|--|--------------|---------|--|----|--|--|--|------|
|  |  | 125 mg/ml    | 20-25°C |  | 24 |  |  |  | 4634 |
|  |  | 50 mg/ml     | 25°C    |  | 7  |  |  |  | 1814 |
|  |  | 50 mg/ml     | 5°C     |  | 22 |  |  |  | 1814 |
|  |  | 12,5 mg/ml   | 35°C    |  | 12 |  |  |  | 4247 |
|  |  | 12,5 mg/ml   | 4°C     |  | 72 |  |  |  | 4247 |
|  |  | 25 mg/ml     | 35°C    |  | 12 |  |  |  | 4247 |
|  |  | 25 mg/ml     | 4°C     |  | 72 |  |  |  | 4247 |
|  |  | 5 & 40 mg/ml | 25°C    |  | 24 |  |  |  | 604  |
|  |  | 5 & 40 mg/ml | 4°C     |  | 10 |  |  |  | 604  |



### Stabilité en mélange

|  |    | 10 mg/ml     | 23°C      |  | Cefpirome sulfate : 50 mg/ml                                      | 8  |  | 280  |
|--|----|--------------|-----------|--|---|----|--|------|
|  |    | 10 mg/ml     | 25°C      |  | Clindamycin phosphate : 9 mg/ml                                   | 48 |  | 418  |
|  |    | 10 mg/ml     | 25°C      |  | Clindamycin phosphate : 9 mg/ml<br>Gentamicin sulfate : 0,8 mg/ml | 12 |  | 695  |
|  |    | 20 mg/ml     | 25°C      |  | Ranitidine hydrochloride : 0,5 mg/ml                              | 4  |  | 2355 |
|  |    | 5 mg/ml      | 25°C      |  | Magnesium sulfate : 10 & 20 mg/ml                                 | 20 |  | 630  |
|  |    | 10 mg/ml     | 25°C      |  | Clindamycin phosphate : 9 mg/ml<br>Gentamicin sulfate : 0,8 mg/ml | 1  |  | 695  |
|  |    | 10 mg/ml     | 25°C      |  | Palonosetron hydrochloride : 25 µg/ml                             | 4  |  | 2214 |
|  | RL | 10 mg/ml     | 23°C      |  | Cefpirome sulfate : 50 mg/ml                                      | 8  |  | 280  |
|  |    | 10 mg/ml     | 23°C      |  | Cefpirome sulfate : 50 mg/ml                                      | 8  |  | 280  |
|  |    | 10 mg/ml     | 25°C      |  | Metronidazole : 5 mg/ml   | 7  |  | 631  |
|  |    | 10 mg/ml     | 5°C       |  | Metronidazole : 5 mg/ml   | 12 |  | 631  |
|  |    | 10 mg/ml     | 8°C       |  | Metronidazole : 5 mg/ml   | 3  |  | 671  |
|  |    | 5 & 20 mg/ml | 23°C-25°C |  | Aztreonam : 10 & 20 mg/ml   | 48 |  | 426  |
|  |    | 5 & 20 mg/ml | 4°C-5°C   |  | Aztreonam : 10 & 20 mg/ml   | 7  |  | 426  |
|  |    | 5 mg/ml      | 4°C       |  | Tenoxicam : 0,2 mg/ml   | 72 |  | 1951 |
|  |    | 0,5 mg/ml    | 25°C      |  | Ceftazidime : 0,5 mg/ml   | 2  |  | 3888 |
|  |    | 0,5 mg/ml    | 25°C      |  | Gentamicin sulfate : 0,02 mg/ml                                   | 4  |  | 3888 |
|  |    | 0,125 mg/ml  | 25°C      |  | Ceftazidime : 0,125 mg/ml   | 24 |  | 3651 |
|  |    | 0,5 mg/ml    | 37°C      |  | Ceftazidime : 0,5 mg/ml   | 24 |  | 3888 |

|     |  |             |      |  |                                 |    |  |      |
|-----|--|-------------|------|--|---------------------------------|----|--|------|
| PVC |  | 0,5 mg/ml   | 37°C |  | Gentamicin sulfate : 0,02 mg/ml | 24 |  | 3888 |
| PVC |  | 0,125 mg/ml | 37°C |  | Ceftazidime : 0,125 mg/ml       | 24 |  | 3651 |
| PVC |  | 0,125 mg/ml | 4°C  |  | Ceftazidime : 0,125 mg/ml       | 7  |  | 3651 |
| PVC |  | 0,5 mg/ml   | 4°C  |  | Ceftazidime : 0,5 mg/ml         | 14 |  | 3888 |
| PVC |  | 0,5 mg/ml   | 4°C  |  | Gentamicin sulfate : 0,02 mg/ml | 14 |  | 3888 |
| POF |  | 10 mg/ml    | 23°C |  | Linezolid : 2 mg/ml             | 3  |  | 1659 |
| POF |  | 10 mg/ml    | 4°C  |  | Linezolid : 2 mg/ml             | 7  |  | 1659 |



### Facteur influençant la stabilité

|  |      |           |  |  |             |
|--|------|-----------|--|--|-------------|
|  |      | 400 mg/ml |  |  | 501<br>1371 |
|  |      |           |  |  | 301         |
|  | 37°C |           |  |  | 3651        |
|  | 37°C |           |  |  | 4634        |



### Compatibilités

|  | Cefazolin sodium : 20 mg/ml<br>Aciclovir sodium : 5 mg/ml           |  | 336  |
|--|---|--|------|
|  | Cefazolin sodium : 20 mg/ml<br>Alfentanil hydrochloride : 500 µg/ml |  | 3380 |
|  | Cefazolin sodium : 20 mg/ml<br>Allopurinol sodium : 3 mg/ml         |  | 307  |
|  | Cefazolin sodium : 100 mg/ml<br>Alprostadil : 15 µg/ml              |  | 3201 |
|  | Cefazolin sodium : 20 mg/ml<br>Amifostine : 10 mg/ml                |  | 3    |
|  | Cefazolin sodium : 10 mg/ml   |  | 4440 |
|  | Cefazolin sodium : 20 mg/ml<br>Amifostine : 10 mg/ml                |  | 3    |
|  |   |  | 3549 |
|  | Cefazolin sodium : 20 mg/ml<br>Amiodarone hydrochloride : 4 mg/ml   |  | 385  |
|  |   |  | 4698 |
|  | Cefazolin sodium : 20 mg/ml<br>Anidulafungin : 0.5 mg/ml            |  | 1982 |
|  | Cefazolin sodium : 20 mg/ml<br>Aztreonam : 40 mg/ml                 |  | 99   |

























































|  |  |  |    |      |
|--|--|--|----|------|
|  |  | Cefazolin sodium<br>Bleomycin sulfate  |    | 4154 |
|  |  | Cefazolin sodium : 100 mg/ml<br>Caffeine : 10 mg/ml                                    | ∅  | 3964 |
|  |  | Cefazolin sodium : 100 mg/ml<br>Caspofungin acetate : 0.5 mg/ml                        |    | 2233 |
|  |  | Cefazolin sodium : 100 mg/ml   | RL | 4603 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Amiodarone hydrochloride : 4 mg/ml                      |    | 385  |
|  |  | Cefazolin sodium : 100 mg/ml<br>Amoxicillin sodium / clavulanic acid : 100/10 mg/ml    |    | 3824 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml |    | 921  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Atracurium besylate : 0.5 mg/ml                         |    | 402  |
|  |  | Cefazolin sodium : 5 & 20 mg/ml<br>Aztreonam : 10 & 20 mg/ml                           |    | 426  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Bivalirudin : 5 mg/ml                                   |    | 1713 |
|  |  | Cefazolin sodium<br>Calcium gluconate  |    | 3644 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Caspofungin acetate : 0,7 mg/ml                         |    | 2247 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Cefiderocol sulfate tosylate : 20 mg/mL                 |    | 4528 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Cefpirome sulfate : 50 mg/ml                            |    | 280  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Cefpirome sulfate : 50 mg/ml                            |    | 280  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Cefpirome sulfate : 50 mg/ml                            | RL | 280  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml                   |    | 3828 |
|  |  | Cefazolin sodium : 1 mg/ml<br>Cimetidine hydrochloride : 1.2 & 5 mg/ml                 |    | 1201 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Cimetidine hydrochloride : 3 mg/ml                      |    | 1201 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Cisatracurium besylate : 0.1 mg/ml                      |    | 299  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Cisatracurium besylate : 2 & 5 mg/ml                    |    | 299  |
|  |  | Cefazolin sodium<br>Clindamycin phosphate  |    | 3526 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Clindamycin phosphate : 9 mg/ml                         |    | 418  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Cloxacillin sodium : 100 mg/ml                          |    | 3012 |
|  |  | Cefazolin sodium : 41.6 mg/ml<br>Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml               |    | 4254 |
|  |  | Cefazolin sodium<br>Daunorubicin/cytarabine liposomale : 0,4 mg/mL                     |    | 4654 |

|  |   |  |      |
|--|---|--|------|
|  | Cefazolin sodium : 20 mg/ml<br>Dexmedetomidine : 4 µg/ml                          |  | 1712 |
|  | Cefazolin sodium : 200 mg/ml<br>Diltiazem hydrochloride : 1 mg/ml                 |  | 198  |
|  | Cefazolin sodium : 20 & 200 mg/ml<br>Diltiazem hydrochloride : 5 mg/ml            |  | 198  |
|  | Cefazolin sodium<br>Dimenhydrinate  |  | 2087 |
|  | Cefazolin sodium : 20 mg/ml<br>Docetaxel : 0.9 mg/ml                              |  | 1754 |
|  | Cefazolin sodium : 100 mg/ml<br>Doxapram hydrochloride : 2 mg/ml                  |  | 1802 |
|  | Cefazolin sodium : 20 mg/ml<br>Doxorubicin hydrochloride liposome peg : 0.4 mg/ml |  | 251  |
|  | Cefazolin sodium : 20 mg/ml<br>Enalaprilate : 0.05 mg/ml                          |  | 1315 |
|  | Cefazolin sodium<br>Erythromycin lactobionate                                     |  | 3674 |
|  | Cefazolin sodium : 220 mg/ml<br>Erythromycin lactobionate : 20 mg/ml              |  | 805  |
|  | Cefazolin sodium : 10 mg/ml<br>Esmolol hydrochloride : 10 mg/ml                   |  | 384  |
|  | Cefazolin sodium : 20 mg/ml<br>Etoposide phosphate : 5 mg/ml                      |  | 1410 |
|  | Cefazolin sodium : 20 mg/ml<br>Famotidine   |  | 397  |
|  | Cefazolin sodium : 20 mg/ml<br>Famotidine : 2 mg/ml                               |  | 215  |
|  | Cefazolin sodium : 20 mg/ml<br>Fenoldopam mesylate : 80 µg/ml                     |  | 1803 |
|  | Cefazolin sodium : 20 mg/ml<br>Fentanyl citrate : 50 µg/ml                        |  | 63   |
|  | Cefazolin sodium : 20 mg/ml<br>Fentanyl citrate : 50 µg/ml                        |  | 3380 |
|  | Cefazolin sodium : 20 mg/ml<br>Filgrastim : 30 µg/ml                              |  | 244  |
|  | Cefazolin sodium : 20 mg/ml<br>Fluconazole : 2 mg/ml                              |  | 256  |
|  | Cefazolin sodium : 40 mg/ml<br>Fluconazole : 2 mg/ml                              |  | 496  |
|  | Cefazolin sodium : 20 mg/ml<br>Fludarabine phosphate : 1 mg/ml                    |  | 492  |
|  | Cefazolin sodium : 40 mg/ml<br>Foscarnet sodium : 24 mg/ml                        |  | 73   |
|  | Cefazolin sodium : 20 mg/ml<br>Fosfomycin : 30 mg/ml                              |  | 4055 |
|  | Cefazolin sodium : 100 mg/ml<br>Gallium nitrate : 1 mg/ml                         |  | 91   |
|  | Cefazolin sodium : 20 mg/ml<br>Gemcitabine hydrochloride : 10 mg/ml               |  | 1423 |
|  | Cefazolin sodium<br>Gentamicin sulfate  |  | 3520 |

|  |  |  |  |      |
|--|--|--|--|------|
|  |  | Cefazolin sodium<br>Gentamicin sulfate                                       |  | 3643 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Granisetron hydrochloride : 0.05 mg/ml        |  | 182  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Heparin sodium : 10 & 5000 UI/ml              |  | 2037 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Heparin sodium : 50 UI/ml                     |  | 317  |
|  |  | Cefazolin sodium : 0.333 mg/ml<br>Heparin sodium : 0.667 UI/ml               |  | 1979 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Hetastarch : 60 mg/ml                         |  | 472  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Hetastarch : 60 mg/ml                         |  | 1721 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Hetastarch : 60 mg/ml                         |  | 465  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Hydromorphone hydrochloride : 0.2 mg/ml       |  | 405  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Hydromorphone hydrochloride : 2 >> 40 mg/ml   |  | 226  |
|  |  | Cefazolin sodium : >200 mg/ml<br>Hydromorphone hydrochloride : 2 >> 40 mg/ml |  | 226  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml           |  | 3829 |
|  |  | Cefazolin sodium : 100 mg/ml<br>Ketamine hydrochloride : 50 mg/ml            |  | 2109 |
|  |  | Cefazolin sodium : 10 mg/ml  |  | 1055 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Labetalol hydrochloride : 1 mg/ml             |  | 386  |
|  |  | Cefazolin sodium : 225 mg/ml   |  | 999  |
|  |  | Cefazolin sodium : 41.6 mg/ml<br>Levetiracetam : 5.21 & 20.83 mg/ml          |  | 4254 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Magnesium sulfate : 16.67 >> 100 mg/ml        |  | 1047 |
|  |  | Cefazolin sodium : 5 mg/ml<br>Magnesium sulfate : 10 & 20 mg/ml              |  | 630  |
|  |  | Cefazolin sodium : 100 mg/ml<br>Meropenem : 50 mg/ml                         |  | 4319 |
|  |  | Cefazolin sodium<br>Metronidazole  |  | 3594 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Morphine sulfate : 1 mg/ml                    |  | 405  |
|  |  | Cefazolin sodium : 41.6 mg/ml<br>Nefopam : 0.16 mg/ml                        |  | 4254 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Nicardipine hydrochloride : 0.1 mg/ml         |  | 1490 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Pancuronium bromide : 0.05 mg/ml              |  | 402  |
|  |  | Cefazolin sodium : 41.6 mg/ml<br>Pantoprazole sodium : 4 mg/ml               |  | 4254 |
|  |  | Cefazolin sodium<br>Pantoprazole sodium                                      |  | 2090 |

|  |  |  |      |      |
|--|--|--|------|------|
|  |  | Cefazolin sodium : 100 mg/ml<br>Paracetamol : 10 mg/ml                       |      | 4742 |
|  |  | Cefazolin sodium : 20 mg/ml  |      | 301  |
|  |  | Cefazolin sodium : 20 mg/ml  |      | 1415 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Idarubicin hydrochloride : 1 mg/ml            |      | 491  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Insulin : 0.2 UI/ml                           |      | 129  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Lansoprazole : 0.55 mg/ml                     |      | 1625 |
|  |  | Cefazolin sodium : 41.6 mg/ml<br>Levofloxacin : 5 mg/ml                      |      | 4254 |
|  |  | Cefazolin sodium<br>Lidocaine hydrochloride                                  |      | 499  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Linezolid : 2 mg/ml                           |      | 1925 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Linezolid : 2 mg/ml                           |      | 1659 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Melphalan : 0.1 mg/ml                         |      | 169  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Metronidazole : 5 mg/ml                       |      | 631  |
|  |  | Cefazolin sodium : 10 mg/ml<br>Metronidazole : 5 mg/ml                       |      | 1035 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Midazolam hydrochloride : 1 mg/ml             |      | 176  |
|  |  | Cefazolin sodium<br>N-acetylcysteine : 200 mg/ml                             |      | 3766 |
|  |  | Cefazolin sodium : 100 mg/ml<br>Naloxone hydrochloride : 0.4 mg/ml           |      | 3408 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Ondansetron hydrochloride : 1 mg/ml           |      | 334  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Palonosetron hydrochloride : 50 µg/ml         |      | 2214 |
|  |  | Cefazolin sodium : 20 >> 40 mg/ml<br>Pantoprazole sodium : 0.16 >> 0.8 mg/ml |      | 1902 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Pemetrexed disodium : 20 mg/ml                |      | 1953 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Pentamidine isetionate : 3 mg/ml              |      | 275  |
|  |  | Cefazolin sodium : 0,1 mg/ml   | <br> | 4693 |
|  |  | Cefazolin sodium : 10 mg/ml<br>Pethidine hydrochloride : 0,5 mg/ml           |      | 111  |
|  |  | Cefazolin sodium : 20 mg/ml<br>Piritramide : 7.5 mg/ml                       |      | 3380 |
|  |  | Cefazolin sodium : 400 mg/ml   |      | 501  |
|  |  | Cefazolin sodium : 400 mg/ml   |      | 1371 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Plazomicin sulfate : 24 mg/ml                 |      | 4145 |



|   |   |   |  |      |
|---|---|---|--|------|
|     |     | Cefazolin sodium : 10 mg/ml<br>Promethazine hydrochloride : 25 mg/ml        |     | 103  |
|   |    | Cefazolin sodium : 20 mg/ml<br>Propofol : 10 mg/ml                          |    | 300  |
|    |    | Cefazolin sodium<br>Protamine sulfate                                       |  | 2071 |
|   |    | Cefazolin sodium : 20 mg/ml<br>Ranitidine hydrochloride : 1 mg/ml           |    | 2355 |
|   |    | Cefazolin sodium : 20 mg/ml<br>Remifentanyl hydrochloride : 25 & 250 µg/ml  |    | 59   |
|    |    | Cefazolin sodium<br>Rocuronium bromide                                      |  | 3564 |
|   |    | Cefazolin sodium : 100 mg/ml<br>Salbutamol sulfate : 1 mg/ml                |    | 3216 |
|   |    | Cefazolin sodium : 20 mg/ml<br>Sargramostim : 10 µg/ml                      |    | 335  |
|   |    | Cefazolin sodium : 20 mg/ml<br>Sufentanil citrate : 0.005 mg/ml             |  | 3380 |
|   |    | Cefazolin sodium : 250 mg/ml<br>Sugammadex : 100 mg/ml                      |    | 3372 |
|   |    | Cefazolin sodium : 20 mg/ml<br>Sulbactam/durlobactam : 15/15 mg/ml          |    | 4801 |
|   |   | Cefazolin sodium : 40 mg/ml<br>Tacrolimus : 1000 µg/ml                      |   | 479  |
|   |  | Cefazolin sodium : 20 mg/ml<br>Tedizolid phosphate : 0.8 mg/ml              |  | 3827 |
|   |  | Cefazolin sodium : 20 mg/ml<br>Teniposide : 0.1 mg/ml                       |  | 905  |
|   |  | Cefazolin sodium : 5 mg/ml<br>Tenoxicam : 0,2 mg/ml                         |  | 1951 |
|   |  | Cefazolin sodium : 20 mg/ml<br>Theophylline : 4 mg/ml                       |  | 317  |
|  |  | Cefazolin sodium : 100 mg/ml<br>Thiopental sodium : 25 mg/ml                |  | 3767 |
|   |  | Cefazolin sodium : 20 mg/ml<br>Thiotepa : 1 mg/ml                           |  | 249  |
|   |  | Cefazolin sodium : 1 ; 10 & 200 mg/ml<br>Vancomycin hydrochloride : 2 mg/ml |  | 1674 |
|  |  | Cefazolin sodium : 50 mg/ml<br>Vancomycin hydrochloride : 2 mg/ml           |  | 1674 |
|  |  | Cefazolin sodium : 10 >> 200 mg/ml<br>Vancomycin hydrochloride : 20 mg/ml   |  | 1674 |
|   |  | Cefazolin sodium : 1 mg/ml<br>Vancomycin hydrochloride : 20 mg/ml           |  | 1674 |
|   |  | Cefazolin sodium : 10 mg/ml<br>Vecuronium bromide : 0.1 mg/ml               |  | 402  |
|   |  | Cefazolin sodium : 2 mg/ml<br>Verapamil hydrochloride : 0.08 mg/ml          |  | 1057 |
|  |  | Cefazolin sodium : 20 mg/ml<br>Vinorelbine tartrate : 1 mg/ml               |  | 84   |
|   |  | Cefazolin sodium : 20 mg/ml<br>Warfarin sodium : 2 mg/ml                    |  | 315  |



## Voie d'administration



## Bibliographie

|     | Type  | Source  |
|-----|-------|---|
| 3   | Revue | Trissel LA, Martinez JF.<br>Compatibility of amifostine with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2208-2212.   |
| 59  | Revue | Trissel LA, Gilbert DL, Martinez JF, Kim MC.<br>Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2192-2196.                   |
| 63  | Revue | Marquardt Ed, Lam SSY.<br>Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 811-812.  |
| 73  | Revue | Lor E, Takagi J.<br>Visual compatibility of foscarnet with other injectable drugs.<br>Am J Hosp Pharm 1990 ; 47: 157-159.   |
| 84  | Revue | Trissel LA, Martinez JF.<br>Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 495-499. |
| 91  | Revue | Lober CA, Dollard PA.<br>Visual compatibility of gallium nitrate with selected drugs during Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 1208-1210.  |
| 99  | Revue | Trissel LA, Martinez JF.<br>Compatibility of aztreonam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 1086-1090.  |
| 103 | Revue | Erickson SH, Ulici D.<br>Incompatibility of cefotetan disodium and promethazine hydrochloride.<br>Am J Health-Syst Pharm 1995 ; 52: 1347.   |
| 111 | Revue | Lee DKT, Wong CY, Wang DP.<br>Stability of cefazolin sodium and meperidine hydrochloride.<br>Am J Health-Syst Pharm 1996 ; 53: 1608,1610.   |
| 129 | Revue | Smythe M, Malouf E.<br>Visual compatibility of insulin with secondary intravenous drugs in admixtures.<br>Am J Hosp Pharm 1991 ; 48: 125-126.   |
| 169 | Revue | Trissel LA, Martinez JF.<br>Physical compatibility of melphalan with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1993 ; 50: 2359-2363.  |
| 176 | Revue | Mantong ML, Marquardt ED.<br>Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 2567-2568.                                       |
| 182 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 56-60.                                |

|     |       |  |
|-----|-------|--|
| 198 | Revue | Gayed AA, Kheshary PR, Hinkle RL.<br>Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 516-520.                                |
| 215 | Revue | Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.<br>Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.<br>Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 226 | Revue | Walker SE, DeAngelis C, Iazzetta J.<br>Stability and compatibility of combinations of hydromorphone and a second drug.<br>Can J Hosp Pharm 1991 ; 44: 289-295.   |
| 244 | Revue | Trissel LA, Martinez JF.<br>Compatibility of filgrastim with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1907-1913.   |
| 249 | Revue | Trissel LA, Martinez JF.<br>Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1996 ; 53: 1041-1045.  |
| 251 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2708-2713.                |
| 256 | Revue | Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.<br>Stability of fluconazole in commonly used intravenous antibiotic solutions.<br>Am J Hosp Pharm 1993 ; 50: 1206-1208.  |
| 275 | Revue | Lewis JD, El-Gendy A.<br>Cephalosporin-pentamidine isethionate incompatibilities.<br>Am J Health-Syst Pharm 1996 ; 53: 1461-1462.  |
| 280 | Revue | Allen LV, Stiles ML, Prince SJ, Sylvestri MF.<br>Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 2427-2433.               |
| 299 | Revue | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1735-1741.  |
| 300 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1287-1292.                                      |
| 301 | Revue | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.<br>Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1295-1300.   |
| 307 | Revue | Trissel LA, Martinez JF.<br>Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1792-1799.   |
| 315 | Revue | Bahal SM, Lee TJ, McGinnes M, Dobler GL.<br>Visual compatibility of warfarin sodium injection with selected medications and solutions.<br>Am J Health-Syst Pharm 1997 ; 54: 2599-2600.   |
| 317 | Revue | Kershaw BP, Monnier HL, Mason JH.<br>Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.<br>Am J Hosp Pharm 1993 ; 50: 1360-1362.  |
| 334 | Revue | Trissel LA, Tramonte SM, Grilley BJ.<br>Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 988-992.  |

|     |       |   |
|-----|-------|---|
| 335 | Revue | Trissel LA, Bready BB, Kwan JW, Santiago NM.<br>Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 | Revue | Forman JK, Lachs JR, Souney PF.<br>Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1987 ; 44: 1408-1409.  |
| 384 | Revue | Colucci RD, Cobuzzi LE, Halpern NA.<br>Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 630-632.   |
| 385 | Revue | Benedict MK, Roche VF, Banakar UV, Hilleman DE.<br>Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 1117-1118.                   |
| 386 | Revue | Colucci RD, Cobuzzi LE, Halpern NA.<br>Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 1357-1358.                          |
| 397 | Revue | Fong PA, Ward J.<br>Visual compatibility of intravenous famotidine with selected drugs.<br>Am J Hosp Pharm 1989 ; 46: 125-126.  |
| 402 | Revue | Savitsky ME.<br>Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1990 ; 47: 820-821.   |
| 405 | Revue | Nieves-Cordero AL, Luciw HM, Souney PF.<br>Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.<br>Am J Hosp Pharm 1985 ; 42: 1108-1109.                                       |
| 418 | Revue | Bosso JA, Townsend RJ.<br>Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions.<br>Am J Hosp Pharm 1985 ; 42: 2211-2214.              |
| 426 | Revue | Riley CM, James MJ.<br>Stability of intravenous admixtures containing aztreonam and cefazolin.<br>Am J Hosp Pharm 1986 ; 43: 925-927.   |
| 440 | Revue | Stiles ML, Tu YH, Allen LV.<br>Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs.<br>Am J Hosp Pharm 1989 ; 46: 1408-1412.  |
| 465 | Revue | Wohlford JG, Wright JC, Wilson MR.<br>More information on the visual compatibility of hetastarch with injectable critical-care drugs.<br>Am J Hosp Pharm 1990 ; 47: 297-298.  |
| 472 | Revue | Wohlford JG, Fowler MD.<br>Visual compatibility of hetastarch with injectable critical-care drugs.<br>Am J Hosp Pharm 1989 ; 46: 995-996.   |
| 479 | Revue | Min DI, Brown T, HWang GC.<br>Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 2964-2966.   |
| 491 | Revue | Turowski RC, Durthaler JM.<br>Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2181-2184.  |

|     |             |   |
|-----|-------------|---|
| 492 | Revue       | Trissel LA, Parks NPT, Santiago NM.<br>Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 | Revue       | Lor E, Sheybani T, Takagi J.<br>Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1991 ; 48: 744-746.  |
| 499 | Revue       | Rockwell K, Burch K.<br>Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient.<br>Hosp Pharm 1991 ; 26: 634-635.   |
| 501 | Revue       | Senholzi CS, Kerns MP.<br>Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection.<br>Am J Hosp Pharm 1985 ; 42: 129-130.   |
| 573 | Revue       | Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL.<br>Stability of antibiotic admixtures frozen in minibags.<br>Drug Intell Clin Pharm 1977 ; 11: 542-548.   |
| 574 | Revue       | Kleinberg ML, Stauffer GL, Prior RB, Latiolais CJ.<br>Stability of antibiotics frozen and stored in disposable hypodermic syringes.<br>Am J Hosp Pharm 1980 ; 37: 1087-1088.  |
| 576 | Revue       | Holmes CJ, Ausman RK, Walter CW, Kundsinn RB.<br>Activity of antibiotic admixtures subjected to different freeze-thaw treatments.<br>Drug Intell Clin Pharm 1980 ; 14: 353-357.   |
| 581 | Revue       | Carone SM, Bornstein M, Coleman DL, Thomas PN, Boylan JC.<br>Stability of frozen solutions of cefazolin sodium.<br>Am J Hosp Pharm 1976 ; 33: 639-641.  |
| 582 | Revue       | Tomecko GW, Kleinberg ML, Latiolais CL, Proior RB, Pesko LJ, Jones BC.<br>Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation.<br>Am J Hosp Pharm 1980 ; 37: 211-215.                       |
| 604 | Laboratoire | Stabilité des médicaments dans l'Intermate® SV50, 100, 200<br>Baxter 1998   |
| 630 | Revue       | Das Gupta V, Stewart KR.<br>Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions.<br>J Clin Hosp Pharm 1985 ; 10: 67-72.   |
| 631 | Revue       | Das Gupta V, Stewart KR.<br>Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion.<br>J Parenter Sci Technol 1985 ; 39: 145-148.           |
| 656 | Revue       | Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J.<br>Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions.<br>J Clin Pharm Ther 1996 ; 21: 185-189.  |
| 671 | Revue       | Rivers TE, McBride HA, Trang JM.<br>Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture.<br>J Parenter Sci Technol 1993 ; 47: 135-137.  |
| 695 | Revue       | Zbrozek AS, Marble DA, Bosso JA.<br>Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions.<br>Drug Intell Clin Pharm 1988 ; 22: 873-875.                        |
| 805 | Revue       | Oskroba DM, Leissing NC, Trissel LA.<br>An automated process for determining the physical compatibility of drugs.<br>Hosp Pharm 1997 ; 32: 1013-1020.   |

|      |       |   |
|------|-------|---|
| 905  | Revue | Trissel LA, Martinez JF.<br>Screening teniposide for Y-site physical incompatibilities.<br>Hosp Pharm 1994 ; 29: 1010-1017.   |
| 921  | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 284-292.                 |
| 999  | Revue | Watson D.<br>Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.<br>JPEN 1985 ; 9: 220-224.  |
| 1035 | Revue | Bisaillon S, Sarrazin R.<br>Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.<br>J Parenter Sci Technol 1983 ; 37: 129-132.   |
| 1047 | Revue | Souney PF, Colucci RD, Mariani G, Campbell D.<br>Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.<br>Am J Hosp Pharm 1984 ; 41: 323-324.  |
| 1055 | Revue | Faragos S.<br>Compatibility of antibiotics and other drugs in total parenteral nutrition solutions.<br>Can J Hosp Pharm 1983 ; 36: 43-52.   |
| 1057 | Revue | Cutie MR.<br>Compatibility of verapamil hydrochloride injection with commonly used additives.<br>Am J Hosp Pharm 1983 ; 40: 1205-1207.  |
| 1201 | Revue | Yuhás EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.<br>Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.<br>Am J Hosp Pharm 1981 ; 38: 1919-1922.  |
| 1315 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R.<br>Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.<br>Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.           |
| 1371 | Revue | Bornstein M, Templeton RJ.<br>Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection.<br>Am J Hosp Pharm 1985 ; 42: 2436.  |
| 1410 | Revue | Trissel LA, Martinez JF, Simmons M.<br>Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 141-145.  |
| 1415 | Revue | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.<br>Compatibility of medications with 3-in-1 parenteral nutrition admixtures.<br>JPEN 1999 ; 23: 67-74.   |
| 1423 | Revue | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 514-518.   |
| 1452 | Revue | Muller HJ, Howe K, Frank C, Haker I.<br>Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*.<br>Eur Hosp Pharm 2000 ; 6: 17-23. |
| 1490 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R.<br>The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.<br>Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.      |
| 1625 | Revue | Trissel LA, Saenz C, Williams YW, Ingram D.<br>Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2001 ; 5: 314-321.  |

|      |       |   |
|------|-------|---|
| 1659 | Revue | Xu QA, Trissel LA, Williams KY.<br>Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.<br>J Am Pharm Assoc 2000 ; 40: 509-514.   |
| 1674 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 1515-1522. |
| 1712 | Revue | Trissel LA, Saenz CA.<br>Compatibility screening of Precedex during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 230-233.  |
| 1713 | Revue | Trissel LA, Saenz CA.<br>Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 311-315.   |
| 1721 | Revue | Trissel LA, Williams KY, Baker MB.<br>Compatibility screening of Hextend during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2001 ; 5: 69-72.  |
| 1754 | Revue | Trissel LA, Gilbert DL, Wolkin AC.<br>Compatibility of docetaxel with selected drugs during simulated Y-site administration.<br>Int J Pharm Compound 1999 ; 3: 241-244.   |
| 1802 | Revue | Bell MS, Nolt DH.<br>Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.<br>Am J Health-Syst Pharm 2003 ; 60: 193-194.                      |
| 1803 | Revue | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.<br>Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2003 ; 60: 80-85.                |
| 1805 | Revue | Lin YF, Wu CC, Lin SH, Wang DP, Wang CN.<br>Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution.<br>Am J Health-Syst Pharm 2002 ; 59: 2362-2364.                                    |
| 1814 | Revue | Gupta VD.<br>Chemical stability of cefazolin sodium after reconstituting in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.<br>Int J Pharm Compound 2003 ; 7, 2: 152-154.   |
| 1840 | Revue | Xu QA, Trissel LA, Saenz CA et al.<br>Stability of three cephalosporin antibiotics in autodose infusion system bags.<br>J Am Pharm Assoc 2002 ; 42: 428-431.  |
| 1902 | Revue | Walker SE, Wyllie A, Law S.<br>Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.<br>Can J Hosp Pharm 2004 ; 57, 2: 90-96.                                    |
| 1925 | Revue | Trissel LA, Williams KY, Gilbert DL.<br>Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.<br>J Am Pharm Assoc 2000 ; 40: 515-519.      |
| 1951 | Revue | Wang DP, Lee D, Wang CN.<br>Stability of sodium cefazolin and tenoxicam in 5% dextrose.<br>Chin Pharm J 2001 ; 53: 185-189.   |
| 1953 | Revue | Trissel LA, Saenz CA, Ogundele AB, Ingram DS.<br>Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2004 ; 61: 2289-2293.             |
| 1979 | Revue | Wu CC, Wang DP, Wong CY, Lin YF.<br>Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions.<br>Am J Health-Syst Pharm 2002 ; 59: 1537-1538.   |


|      |       |  |
|------|-------|--|
| 1982 | Revue | Trissel LA, Ogundele AB.<br>Compatibility of anidulafungin with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2005 ; 62: 834-837.  |
| 2037 | Revue | Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B.<br>Stability of heparin and physical compatibility of heparin/antibiotic solutions ...<br>J Antimicrob Chemother 2005 ; 56: 951-953.  |
| 2071 | Revue | Ng HP, Koh KF.<br>Precipitation of protamine by cefazolin.<br>Anesth Analg 2002 ; 95: 785.   |
| 2087 | Revue | Ferreira E, Forest JM, Hildgen P.<br>Compatibility of dimenhydrinate injectable by Y administration.<br>Pharmactuel 2004 ; 37: 17-20.  |
| 2090 | Revue | Pere H, Chasse V, Forest JM, Hildgen P.<br>Compatibility of injectable pantoprazole in Y-site administration.<br>Pharmactuel 2004 ; 37: 193-196.   |
| 2109 | Revue | Pelletier E, Forest JM, Hildgen P.<br>Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels.<br>Pharmactuel 2006 ; 39: 71-75.  |
| 2214 | Revue | Ben M, Trusley C, Kupiec T.C, Trissel L.A.<br>Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration.<br>Int J Pharm Compound 2007 ; 11, 6: 520-524.   |
| 2233 | Revue | Condie C.K, Tyler L.S, Barker B, Canann D.M.<br>Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery<br>Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.   |
| 2247 | Revue | Chan P, Heatherly K, Kupiec T.C, Trissel L.A.<br>Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2008 ; 12, 3: 276-278.  |
| 2355 | Revue | Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M.<br>Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium and cephalotin sodium during simulated Y-site administration.<br>Int J Pharm Compound 2000 ; 4, 2: 150-153. |
| 2372 | Revue | Nahata MC, Ahalt PA.<br>Stability of cefazolin sodium in peritoneal dialysis solutions<br>Am J Hosp Pharm 1991 ; 48: 291 - 292.  |
| 3012 | Revue | Sullivan T, Forrest J.M, Leclair G.<br>Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration<br>Hosp Pharm 2015 ; 50, 3: 214-220.   |
| 3201 | Revue | Dice JE.<br>Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.<br>J Pediatr Pharmacol Ther 2006 ; 11:233-236.  |
| 3216 | Revue | Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.<br>Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.<br>Pharmactuel 2011 ; 44, 1 : 14-18  |
| 3230 | Revue | Donnelly RF.<br>Stability of Cefazolin Sodium in Polypropylene Syringes and Polyvinylchloride Minibags<br>Can J Hosp Pharm 2011 ; 64, 4: 241-245.  |
| 3372 | Revue | Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.<br>Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.<br>Rev Bras Anestesiol 2013 ; 63, 1: 163-166.   |




|      |             |  |
|------|-------------|--|
| 3380 | Revue       | Eckle V-S, Heim E, Hahn M, Grasshoff C.<br>Incompatibility of Piritramide with Cephalosporins.<br>Ann Pharmacotherapy 2013 ;47:426-427.  |
| 3408 | Revue       | Tollec S, Touzin K, Pelletier E, Forest J.M.<br>Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels.<br>Pharmactuel 2013 ; 46, 1 : 16-21.  |
| 3520 | Laboratoire | Cidomycin - Summary of product Characteristics.<br>Sanofi 2011   |
| 3526 | Laboratoire | Clindamycin (Dalacin®) - Summary of Product Characteristics<br>Pharmacia 2010  |
| 3549 | Laboratoire | Amikacine B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012  |
| 3564 | Laboratoire | Rocuronium B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012   |
| 3594 | Laboratoire | Metronidazole (Flagyl®) - Summary of Product Characteristics<br>Zentiva 2013   |
| 3643 | Laboratoire | Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics<br>Sanofi 2015   |
| 3644 | Laboratoire | Calcium gluconate® - Summary of Product Characteristics<br>HamelN Pharmaceuticals 2010   |
| 3651 | Revue       | Patel R.P, Shastri M.D, Bakkari M, Wanandy T, Jose M.D.<br>Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution.<br>Perit Dial Int 2014 ; 34:212-218                                  |
| 3674 | Laboratoire | Erythromycin lactobionate - Summary of Product Characteristics<br>PanPharma 2016   |
| 3766 | Revue       | Forrest J.M, Hildgen P.<br>Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels<br>Pharmactuel 2014 ; 47, 3 : 161-165.  |
| 3767 | Revue       | Legris M.E, Lavoie A, Forrest J.M, Hildgen P.<br>Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.<br>Pharmactuel 2014 ; 47, 3 : 167-172.                                  |
| 3824 | Revue       | Boudi S, Roy H, Forest JM, Leclair G.<br>Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.<br>Pharmactuel 2023 2023;56,3:91-98                  |
| 3827 | Poster      | Ghazi I.M, Hamada Y, Nicolau D.P.<br>Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.<br>ASHP Midyear 2015  |
| 3828 | Poster      | Thabit A.K, Hamada Y, Nicolau D.P.<br>Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.<br>ASHP Midyear 2015   |
| 3829 | Poster      | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.<br>Compatibility of isavunazonium sulfate during simulated Y-site administration.<br>ASHP Midyear 2015   |
| 3888 | Revue       | Ranganathan D, Naicker S., Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A<br>Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).<br>Perit Dial Int 2016 ; 36:421-426. |
| 3964 | Revue       | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.<br>Pharmactuel 2017 ; 50,1 : 27-33.   |

|      |             |   |
|------|-------------|---|
| 4055 | Revue       | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.<br>Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 , 75, 1:36-44   |
| 4145 | Revue       | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.<br>Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 ;75,14:1048-1056  |
| 4154 | Laboratoire | Bleomycin sulfate- Summary of Product Characteristics<br>Accord Health Care 2018  |
| 4247 | Revue       | Patel R, Jacob J, Sedeeq M, Ming L.C, Wanandy T, Zaidi S.T.R, Peterson G.M.<br>Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices.<br>Clin Ther 2018 ;40,4:664-667   |
| 4254 | Revue       | D&#39;Huart E, Vigneron J, Demoré B.<br>Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs<br>Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40             |
| 4319 | Revue       | Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G.<br>Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.<br>Hosp Pharm 2020 ; 55, 5: 332-337.   |
| 4440 | Revue       | Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.<br>Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.<br>Ann Nutr Metab 2018 ; 73: 227-233.   |
| 4528 | Revue       | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.<br>Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.<br>Int J Pharm Compound 2021 ;25,1:52-61  |
| 4603 | Revue       | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.<br>Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.<br>Hosp Pharm 2021 ; 56, 4: 228-234.   |
| 4634 | Revue       | Loeuille G, D&#39;Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.<br>Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.<br>Antibiotics 2022 ;11,4: 458 |
| 4654 | Poster      | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.<br>Compatibilité visuelle du Vyxeos® lors d&#39;administration en Y avec une sélection de médicaments injectables.<br>Communication personnelle 2021   |
| 4693 | Revue       | Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L.<br>Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection.<br>Drug Design Dev Ther 2022 ;16:1433-1440.  |
| 4698 | Revue       | Ayari G, D&#39;Huart E, Vigneron J, Demoré B.<br>Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.<br>Pharmaceutical Technology in Hospital Pharmacy 2022  |
| 4742 | Revue       | Macoviciuc M, Nguyen C, Forest J-M, Leclair G.<br>Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y.<br>Pharmactuel 2022 ; 55, 4: 247-255.   |
| 4801 | Revue       | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.<br>Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2024 ;51,1:  |

# Stabilis






## Cefazolin sodium
















### Stabilité des préparations

|  | 16,6 mg Kefzol® (Eli Lilly)    | NaCl 0.9% >> 5 ml   | 4°C   |  | 7  |  |  | 2505 |
|--|--------------------------------|---|-------|--|----|--|--|------|
|  | 16,6 mg Kefzol® (Eli Lilly)    | Tampon acétate pH 4,5 >> 5 ml   | 4°C   |  | 7  |  |  | 2505 |
|  | 16,6 mg Kefzol® (Eli Lilly)    | Tampon acétate pH 5,7 >> 5 ml   | 4°C   |  | 7  |  |  | 2505 |
|  | 500 mg ® = Cefazolin panpharma | NaCl 0.45% >> 10 mL   | 4°C   |  | 30 |  |  | 2707 |
|  | 500 mg ® = Cefazolin panpharma | Thiomersal 0,5 mg<br>Glycérine 100 mg<br>Eau ppi >> 10 ml   | 4°C   |  | 30 |  |  | 2707 |
|  | 200mg Cefazoline               | Eau ppi 1ml<br>Tears Naturele® 3ml  | 2-8°C |  | 28 |  |  | 3155 |
|  | 200mg Cefazoline               | Eau ppi 1ml<br>Natear® 3ml  | 2-8°C |  | 28 |  |  | 3155 |
|  | 500 mg Biofazolin®             | Tampon citrate pH 6.27 - 161 mOsmol/L   | 4°C   |  | 30 |  |  | 3291 |
|  | 500 mg Biofazolin®             | Tampon citrate pH 6.27 - 161 mOsmol/L<br>Borate de phenylmercure 0.04% 250 mg<br>Texte introuvable (10553,) 40 mg   | 4°C   |  | 30 |  |  | 3291 |
|  | 500 mg Biofazolin®             | Tampon citrate pH 6.22 - 308 mOsmol/L<br>Alcool polyvinylique η=42.3 mPa.s pH 4.4<br>Borate de phenylmercure 0.04% 250 mg<br>Texte introuvable (10553,) 40 mg | 4°C   |  | 30 |  |  | 3291 |
|  | 500 mg Biofazolin®             | Tampon citrate pH 6.22 - 308 mOsmol/L<br>Alcool polyvinylique η=42.3 mPa.s pH 4.4   | 4°C   |  | 30 |  |  | 3291 |
|  | 100 mg Biofazolin®             | Tampon citrate pH 6.22 - 308 mOsmol/L   | 4°C   |  | 30 |  |  | 3291 |
|  | 100 mg Biofazolin®             | Tampon citrate pH 6.22 - 308 mOsmol/L<br>Borate de phenylmercure 0.04% 250 mg<br>Texte introuvable (10553,) 40 mg   | 4°C   |  | 30 |  |  | 3291 |
|  | 100 mg Biofazolin®             | Tampon citrate pH 6.11 - 581 mOsmol/L<br>Alcool polyvinylique η=42.3 mPa.s pH 4.4   | 4°C   |  | 30 |  |  | 3291 |

|   |  |                    |  |  |  |  |  |      |
|---|--|--------------------|--|--|--|--|--|------|
| ? |  | 100 mg Biofazolin® | Tampon citrate pH 6.11 - 581 mOsmol/L<br>Alcool polyvinylique $\eta=42.3$ mPa.s pH 4.4<br>Borate de phenylmercure 0.04% 250 mg<br>Texte introuvable (10553,) 40 mg |  0.05 g<br>30 |  |  |  | 3291 |
|---|--|--------------------|--|--|--|--|--|------|



### Facteur influençant la stabilité

|   |   |      |   |   |              |
|---|---|------|---|---|--------------|
|  |  |      |  |  | 3155         |
|  |  | 40°C |  |  | 2868         |
|  | 25°C  |      |  |  | 2505<br>2707 |
|   | PH >7   |      |  |  | 2505         |













































































### Bibliographie

|      | Type  | Source  |
|------|-------|---|
| 2505 | Revue | Ahmed I, Day P.<br>Stability of cefazolin sodium in various artificial tear solutions and aqueous vehicles<br>Am J Hosp Pharm 1987 ; 44: 2287-2290  |
| 2707 | Revue | How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY.<br>Stability of cefazolin sodium eye drops<br>J Clin Pharm Ther 1998 ; 23, 1: 41-47.   |
| 2868 | Revue | Kommanaboyina B, Lindauer RF, Rhodes CT, Grady LT.<br>Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution.<br>Int J Pharm Compound 2000 ; 4, 2: 146-149.  |
| 3155 | Revue | Rojanarata T, Tankul J, Woranaipinich C, Potawanich P, Plianwong S, Sakulma S, Saehuan C.<br>Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives.<br>J Ocular Pharm Ther 2010 ; 26, 5: 485-490. |
| 3291 | Revue | Kodym A, Bilski P, Domanska A, Lukasz Helminiak, Jablonska M, Jachymska A.<br>Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method.<br>Acta Pol Pharm 2012 ; 69, 1: 95-105.   |



# Dictionnaire

|  |   |
|--|---|
|  Antibiotique                               |  Injectable                                |
|  Noms commerciaux                           |  Stabilité des solutions                   |
|  Contenant                                  |  Molécule                                  |
|  Concentration                              |  Température                               |
|  Conservation                               |  Durée de stabilité                        |
|  Biosimilaire                               |  Données conflictuelles                    |
|  Bibliographie                              |  Verre                                     |
|  Eau pour préparation injectable            |  A l'abri de la lumière                    |
|  Jour                                       |  NaCl 0,9% ou glucose 5%                   |
|  Lumière                                    |  Heure                                     |
|  Chlorure de sodium 0,9%                    |  Non précisée                              |
|  Glucose 5%                                 |  Polyvinyl chlorure                        |
|  Dianéal® PD1 1.5% glucose (Baxter)        |  Dianéal® PD1 4.25% glucose (Baxter)      |
|  Dianéal® PD2 1.5% glucose (Baxter)       |  Extraneal® (Baxter)                     |
|  Polyolefine                              |  Ethylène vinyl acétate                  |
|  Seringue polypropylène                   |  Elastomère en polyisoprène              |
|  Stabilité en mélange                     |  Solvant                                 |
|  Molécule                                 | <b>RL</b> Ringer lactate  |
|  Chlorure de sodium 0,45%                 |  Aucun                                   |
|  Facteur influençant la stabilité         |  Provoque                                |
|  Précipitation                            |  Nutrition parentérale (mélange binaire) |
|  Dégradation                              |  Diminution de la stabilité              |
|  Compatibilités                           |  Compatible                              |
|  Nutrition parentérale (mélange ternaire) |  Instabilité chimique                    |
|  Incompatible                             |  Précipitation immédiate                 |
|  Incompatibilité non précisée             |  Turbidité immédiate                     |
|  Turbidité à 24 heures                    |  Turbidité en 1 heure                    |
|  Solvant spécifique                       |  Précipitation en 1 heure                |
|  Précipitation en 4 heures                |  Précipitation en 2 heures               |
|  Changement de couleur à 4 heures         |  NaCl 0.225 % + glucose 3.75%            |

|  |  |
|--|--|
|  Voie d'administration       |  Intraveineuse       |
|  Perfusion intraveineuse    |  Perfusion continue |
|  Intramusculaire            |  Intrapéritonéale   |
|  Bibliographie              |  Collyre            |
|  Stabilité des préparations |  Origine            |
|  Excipient                  |  Flacon injectable  |
|  Non précisé                |  Augmentation       |
|  Dictionnaire               |  |